A Holmes1, B D Kelly1, M Perera1, R S Eapen1,2, D M Bolton1, N Lawrentschuk3,4,5,6. 1. Department of Surgery, Austin Hospital, University of Melbourne, Melbourne, VIC, Australia. 2. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 3. Department of Surgery, Austin Hospital, University of Melbourne, Melbourne, VIC, Australia. lawrentschuk@gmail.com. 4. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. lawrentschuk@gmail.com. 5. EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare, Melbourne, Australia. lawrentschuk@gmail.com. 6. Department of Urology, Royal Melbourne Hospital, Melbourne, Australia. lawrentschuk@gmail.com.
Abstract
PURPOSE: The early diagnosis of prostate cancer and subsequent access to the treatment options helps to achieve optimal cancer outcomes. As the treatment options for patients with advanced prostate cancer continues to evolve, patients need to access a multidisciplinary team (MDT) meeting to receive best-practice care. METHODS: In this paper a MEDLINE review was performed to assess clinical decision making in the context of MDT discussions for patients with advanced prostate cancer. RESULTS: From 441 returned articles and abstracts, 50 articles were assessed for eligibility and 16 articles included for analysis. Sixteen articles were identified, 9 of the 16 articles used quantitative methodology including three retrospective analysis of clinical registry data, patient medical records and/or MDT meeting notes and three cross-sectional surveys. Other study designs included one observation study and one study using a combination of qualitative and quantitative methodologies and one mini-review. There were also four editorials included in the review and two consensus statements. CONCLUSION: This paper highlights the important role the inter-disciplinary MDT has on shared decision making for men with advanced prostate cancer. The application of MDT care is a rapidly growing trend in uro-oncology and an efficient MDT service requires further research to assess its efficiency so that it may expand through all aspect of uro-oncology.
PURPOSE: The early diagnosis of prostate cancer and subsequent access to the treatment options helps to achieve optimal cancer outcomes. As the treatment options for patients with advanced prostate cancer continues to evolve, patients need to access a multidisciplinary team (MDT) meeting to receive best-practice care. METHODS: In this paper a MEDLINE review was performed to assess clinical decision making in the context of MDT discussions for patients with advanced prostate cancer. RESULTS: From 441 returned articles and abstracts, 50 articles were assessed for eligibility and 16 articles included for analysis. Sixteen articles were identified, 9 of the 16 articles used quantitative methodology including three retrospective analysis of clinical registry data, patient medical records and/or MDT meeting notes and three cross-sectional surveys. Other study designs included one observation study and one study using a combination of qualitative and quantitative methodologies and one mini-review. There were also four editorials included in the review and two consensus statements. CONCLUSION: This paper highlights the important role the inter-disciplinary MDT has on shared decision making for men with advanced prostate cancer. The application of MDT care is a rapidly growing trend in uro-oncology and an efficient MDT service requires further research to assess its efficiency so that it may expand through all aspect of uro-oncology.
Authors: Heather L Colquhoun; Danielle Levac; Kelly K O'Brien; Sharon Straus; Andrea C Tricco; Laure Perrier; Monika Kastner; David Moher Journal: J Clin Epidemiol Date: 2014-07-14 Impact factor: 6.437
Authors: Marco Bandini; Felix Preisser; Sebastiano Nazzani; Michele Marchioni; Zhe Tian; Nicola Fossati; Giorgio Gandaglia; Andrea Gallina; Firas Abdollah; Shahrokh F Shariat; Francesco Montorsi; Fred Saad; Derya Tilki; Alberto Briganti; Pierre I Karakiewicz Journal: Eur Urol Focus Date: 2018-02-01
Authors: Josep M Borras; Tit Albreht; Riccardo Audisio; Erik Briers; Paolo Casali; Hélène Esperou; Birgitte Grube; Marc Hamoir; Geoffrey Henning; Joan Kelly; Susan Knox; Maria Nabal; Marco Pierotti; Claudio Lombardo; Wim van Harten; Graeme Poston; Joan Prades; Milena Sant; Luzia Travado; Vincenzo Valentini; Cornelis van de Velde; Saskia van den Bogaert; Marc van den Bulcke; Elke van Hoof; Ingrid van den Neucker; Robin Wilson Journal: Eur J Cancer Date: 2013-12-06 Impact factor: 9.162
Authors: William T Lowrance; Mohammad Hassan Murad; William K Oh; David F Jarrard; Matthew J Resnick; Michael S Cookson Journal: J Urol Date: 2018-08-04 Impact factor: 7.450
Authors: Carlo Andrea Bravi; Amy Tin; Emily Vertosick; Elio Mazzone; Marco Bandini; Paolo Dell'Oglio; Armando Stabile; Giorgio Gandaglia; Nicola Fossati; Daniel Sjoberg; Karim Touijer; Cesare Cozzarini; Alberto Briganti; Francesco Montorsi; James Eastham; Andrew Vickers Journal: Urol Oncol Date: 2019-10-23 Impact factor: 3.498